This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Leukemia	2-Hydroxyglutarate (2-HG); isocitrate dehydrogenase 1 (IDH1)	Cell culture studies suggest inhibiting the (<i>R</i>)-enantiomer of 2-HG could help treat leukemia. In two human leukemia cell lines, a membrane-permeable version of (<i>R</i>)-2-HG promoted leukemic transformation, whereas (<i>S</i>)-2-HG and vehicle did not. In the two cell lines, a compound that blocked 2-HG production by a cancer-associated mutant <i>IDH1</i> reversed the markers of leukemic transformation, whereas vehicle did not. Next steps include evaluating the inhibition of (<i>R</i>)-2-HG signaling in leukemia mouse models and in other types of IDH1-driven cancers.	Unpatented; licensing status not applicable	Losman, J.-A. <i>et al. Science</i> ; published online Feb. 7, 2013; doi:10.1126/science.1231677 Contact: William Kaelin Jr., Dana-Farber Cancer Institute, Boston, Mass. e-mail: william_kaelin@dfci.harvard.edu
<i>SciBX</i> 6(8); doi:10.1038/scibx.2013.193 Published online Feb. 28, 2013				